MarketPeel
Insider Trading Intelligence
Pricing
…
YY

Yong Yu

GNLX
SVP, CLINICAL DEVELOPMENT · GENELUX CORP · CIK 0001937482
FILING MIX · LIFETIME38%/62%
BUYS
19
SELLS
31
TOTAL VALUE
$3.44M
COMPANIES
1
ACTIVE SINCE
Feb 2023
HOLDINGS NOW
269,024
AVG SELL PX
$15.52
TRADE KIND
SHOWING 50 / 50
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
25 backtested trades · 8 horizons · 11 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Yong Yu, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d25+36.00%+1.86%+0.00%+1.86%+0.41%—
14d25+44.00%+0.05%+0.57%-0.55%-3.86%—
30d25+52.00%-8.31%+1.06%-9.37%-4.55%—
60d25(1 pending)+66.67%-19.43%+4.53%-25.68%-36.68%—
90d25(1 pending)+79.17%-28.44%+8.81%-37.25%-44.87%—
180d25(2 pending)+86.96%-55.10%+16.73%-71.83%-88.36%—
1y25(3 pending)+81.82%-70.37%+29.08%-99.45%-115.82%—
2y25(4 pending)+95.24%-60.78%+51.83%-119.80%-131.80%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
GNLX · 269,024 shares · as of Jun 16, 2026
067,256134,512201,768269,024202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 19 buys / 31 sellsCOVERAGE · 14 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
119,318——269,024Jun 16, 2026Jun 18, 2026 ↗View →
GNLX
GENELUX CORP
SALE
Chief Scientific Officer
605$2.97$1.8K149,706May 11, 2026May 12, 2026 ↗View →
GNLX
GENELUX CORP
SALE
SVP, Clinical Development
906$2.42$2.2K144,938Mar 24, 2026Mar 26, 2026 ↗View →
GNLX
GENELUX CORP
SALE
SVP, Clinical Development
973$5.37$5.2K145,844Nov 17, 2025Dec 11, 2025 ↗View →
GNLX
GENELUX CORP
SALE
SVP, Clinical Development
207,652——0Sep 1, 2025Sep 3, 2025 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
207,652——207,652Sep 1, 2025Sep 3, 2025 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
65,000——65,000Sep 1, 2025Sep 3, 2025 ↗View →
GNLX
GENELUX CORP
SALE
SVP, Clinical Development
65,000——0Sep 1, 2025Sep 3, 2025 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
134,520——134,520Aug 27, 2025Aug 29, 2025 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
101,480——150,036Aug 27, 2025Aug 29, 2025 ↗View →
GNLX
GENELUX CORP
SALE
SVP, Clinical Development
3,219$3.36$10.8K146,817Aug 21, 2025Dec 11, 2025 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
5,579$2.92$16.3K47,640May 12, 2025May 13, 2025 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
13,350——53,219Mar 14, 2025Apr 17, 2025 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
29,000——39,869Dec 18, 2024Dec 20, 2024 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
39,000——39,000Dec 18, 2024Dec 20, 2024 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
6,849$2.12$14.5K10,869Jun 24, 2024Jul 8, 2024 ↗View →
GNLX
GENELUX CORP
PURCHASE
VP, Clinical Trial Operations
2,500——2,500May 29, 2024Jun 7, 2024 ↗View →
GNLX
GENELUX CORP
PURCHASE
VP, Clinical Trial Operations
2,500——2,500May 29, 2024Jun 7, 2024 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
11,557——17,718Mar 14, 2024Jul 8, 2024 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
3,661——6,161Feb 19, 2024Jul 8, 2024 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
5,803$14.18$82.3K0Dec 15, 2023Dec 18, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
26,732$12.94$345.9K5,803Dec 15, 2023Dec 18, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
36,800$11.85$436.0K32,535Dec 7, 2023Dec 8, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
18,665$10.26$191.6K69,335Nov 21, 2023Nov 22, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
14,594$11.26$164.3K88,000Nov 20, 2023Nov 21, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
3,541$13.04$46.2K102,594Nov 17, 2023Nov 21, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
5,200——207,653Oct 24, 2023Oct 25, 2023 ↗View →
GNLX
GENELUX CORP
PURCHASE
VP, Clinical Trial Operations
5,200$6.00$31.2K111,335Oct 24, 2023Oct 25, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
5,200$19.11$99.4K106,135Oct 24, 2023Oct 25, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
4,800$21.94$105.3K106,535Oct 10, 2023Oct 11, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
400$22.91$9.2K106,135Oct 10, 2023Oct 11, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
5,200——212,853Oct 10, 2023Oct 11, 2023 ↗View →
GNLX
GENELUX CORP
PURCHASE
VP, Clinical Trial Operations
5,200$6.00$31.2K111,335Oct 10, 2023Oct 11, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
2,203$24.46$53.9K106,135Sep 26, 2023Sep 27, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
1,883$22.54$42.4K109,452Sep 26, 2023Sep 27, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
1,114$23.51$26.2K108,338Sep 26, 2023Sep 27, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
5,200——218,053Sep 26, 2023Sep 27, 2023 ↗View →
GNLX
GENELUX CORP
PURCHASE
VP, Clinical Trial Operations
5,200$6.00$31.2K111,335Sep 26, 2023Sep 27, 2023 ↗View →
GNLX
GENELUX CORP
PURCHASE
VP, Clinical Trial Operations
6,000$6.00$36.0K112,135Sep 20, 2023Sep 21, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
6,000$27.96$167.8K106,135Sep 20, 2023Sep 21, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
6,000——223,253Sep 20, 2023Sep 21, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
10,400——229,253Sep 15, 2023Sep 18, 2023 ↗View →
GNLX
GENELUX CORP
PURCHASE
VP, Clinical Trial Operations
10,400$6.00$62.4K116,535Sep 15, 2023Sep 18, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
4,675$22.29$104.2K106,135Sep 15, 2023Sep 18, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
5,725$21.56$123.4K110,810Sep 15, 2023Sep 18, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
29,800$21.14$629.9K106,135Sep 13, 2023Sep 15, 2023 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
65,000——65,000Sep 11, 2023Sep 12, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
19,800$24.70$489.1K135,935Aug 30, 2023Aug 30, 2023 ↗View →
GNLX
GENELUX CORP
SALE
VP, Clinical Trial Operations
3,265$23.73$77.5K155,735Aug 18, 2023Aug 22, 2023 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
9,000——159,000Feb 17, 2023May 2, 2023 ↗View →
Other insiders · GNLX
Loading peer insiders…
About this filer
CIK 0001937482
ROLE
SVP, Clinical Development
PRIMARY
GNLX
COMPANIES
1
ACTIVE SINCE
Feb 2023
MARKETPEEL · /INSIDER/0001937482DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback